ImCheck Therapeutics raises €20 Million and appoints its CEO

|   Financial & Business

Emerging leader in immuno-oncology accelerates its development programs and prepares for entry into the clinic

Marseille, France, May 2nd 2017 (5:45 PM CEST) – ImCheck Therapeutics, an emerging player in the field of cancer and auto-immunity, today announced the completion of a €20 Million Series A financing round led by Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, Idinvest and joined by Gimv and LSP. ImCheck is developing a new generation of proprietary immuno-modulatory antibodies acting on both adaptive and innate immunity (notably gamma-delta T-cells).

In conjunction with this financing, ImCheck appointed Pierre d’Epenoux as Chief Executive Officer. Pierre brings with him two decades of operational management and corporate development experience in pharma and biotech.

It is a rare opportunity to drive to clinic cutting-edge science in the red-hot competitive area of immuno-oncology. With the favorable bench-to-bedside environment offered by the Marseille Cancer Research Center and the Paoli-Calmettes Cancer Institute, Daniel Olive and his team have built a worldwide renowned expertise in the co-signaling pathways regulating the innate and the adaptive immune systems as well as demonstrate their ability to develop & partner innovative drug candidatessaid Pierre d’Epenoux. “I am delighted to join Imcheck at this exciting development stage of the company and together with its outstanding team, quickly put on the map a novel class of drugs with the potential to overcome resistance to currently available treatments for cancer & auto-immune diseases”.

Imcheck’s ability to attract renowned international investors and great managerial talents, with experience in building strategic organizations and structuring long-term valuable partnerships confirms the attractiveness of the science and the potential of this new force in immuno-oncologysaid Dr. Rémi Droller, Managing Partner at Kurma Partners and ImCheck’s Chairman of the Board.

The significant funding raised at this stage of development of the company will provide the resources for an ambitious development plan of several drug-candidates and entry into the clinic by 2019”, added Prof. Daniel Olive.